Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Go back to Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 213.00 -7.83 (3.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $220.83 | 52 Week High | $333.65 | |||
| Open | $215.45 | 52 Week Low | $223.02 | |||
| Day High | $217.28 | P/E | 27.27 | |||
| Day Low | $210.54 | EPS | $7.81 | |||
| Volume | 372,939 | |||||
